BioCentury | Oct 30, 2006
Company News

Baxter, GenOdyssee deal

...rights to resulting products. Further terms were not disclosed. Baxter International Inc. (BAX), Deerfield, Ill. GenOdyssee S.A....
BioCentury | Oct 16, 2006
Clinical News

GenOdyssee preclinical data

...variants or with standard IFN alpha-2b. GEA007.1 is an antiviral interferon (IFN) alpha 17 variant. GenOdyssee S.A....
BioCentury | Jun 9, 2003
Company News

Debiopharm, GenOdyssee deal

...to develop and commercialize a GenOdyssee compound. The compound will be selected from a predefined GenOdyssee...
...first development rights for all other indications and sole manufacturing rights for the licensed compound. GenOdyssee...
...Phase III trails, and a share of the out-licensing revenues. Debiopharm S.A. , Lausanne, Switzerland GenOdyssee S.A....
BioCentury | Jun 4, 2003
Company News

Debiopharm, GenOdyssee cancer deal

...to develop and commercialize a GenOdyssee compound. The compound will be selected from a predefined GenOdyssee...
...first development rights for all other indications and sole manufacturing rights for the licensed molecule. GenOdyssee...
BioCentury | Mar 3, 2003
Emerging Company Profile

GenOdyssee: Better blockbusters

...Although protein therapeutics have attained blockbuster status, GenOdyssee S.A. sees an opportunity to make many such therapies...
...a low dose would keep the same toxicity in humans but give higher efficacy." Because GenOdyssee...
...those methods because the proteins have never been in man before. To find improved proteins, GenOdyssee...
BioCentury | Mar 3, 2003
Emerging Company Profile

Corporate Profile

GenOdyssee S.A. Les Ulis, France Technology: Functional SNP discovery and validation applied to genes coding for therapeutic proteins Disease focus: Viral infection, cancer, anemia, autoimmune disease Clinical status: Preclinical Founded: 1999 by Jean-Louis Escary Corporate...
BioCentury | Sep 30, 2002
Company News

GenOdyssee board of directors update

GenOdyssee S.A. , Les Ulis, France Business: Functional genomics Appointed: Jean-Marc Giry, VP of strategic planning; Philippe Remes, VP of investor relations; Jean Maral VP of preclinical and clinical affairs WIR Staff...
BioCentury | Sep 30, 2002
Company News

GenOdyssee management update

GenOdyssee S.A. , Les Ulis, France Business: Functional genomics Hired: Jean-Marc Giry as VP of strategic planning, formerly X-PM Transition Partners; Philippe Remes as VP of investor relations, formerly VP of Northern Europe at Tyco Healthcare...
BioCentury | Sep 23, 2002
Company News

GenOdyssee SA other research news

...and suggest that the IFN alpha variants are better tolerated than those on the market GenOdyssee...
BioCentury | Jan 14, 2002
Company News

GenOdyssee, Transgenomic sales and marketing update

...market nucleic acid analysis services performed by GenOdyssee in the U.S., EU, Switzerland and Japan. GenOdyssee S.A....
Items per page:
1 - 10 of 11
BioCentury | Oct 30, 2006
Company News

Baxter, GenOdyssee deal

...rights to resulting products. Further terms were not disclosed. Baxter International Inc. (BAX), Deerfield, Ill. GenOdyssee S.A....
BioCentury | Oct 16, 2006
Clinical News

GenOdyssee preclinical data

...variants or with standard IFN alpha-2b. GEA007.1 is an antiviral interferon (IFN) alpha 17 variant. GenOdyssee S.A....
BioCentury | Jun 9, 2003
Company News

Debiopharm, GenOdyssee deal

...to develop and commercialize a GenOdyssee compound. The compound will be selected from a predefined GenOdyssee...
...first development rights for all other indications and sole manufacturing rights for the licensed compound. GenOdyssee...
...Phase III trails, and a share of the out-licensing revenues. Debiopharm S.A. , Lausanne, Switzerland GenOdyssee S.A....
BioCentury | Jun 4, 2003
Company News

Debiopharm, GenOdyssee cancer deal

...to develop and commercialize a GenOdyssee compound. The compound will be selected from a predefined GenOdyssee...
...first development rights for all other indications and sole manufacturing rights for the licensed molecule. GenOdyssee...
BioCentury | Mar 3, 2003
Emerging Company Profile

GenOdyssee: Better blockbusters

...Although protein therapeutics have attained blockbuster status, GenOdyssee S.A. sees an opportunity to make many such therapies...
...a low dose would keep the same toxicity in humans but give higher efficacy." Because GenOdyssee...
...those methods because the proteins have never been in man before. To find improved proteins, GenOdyssee...
BioCentury | Mar 3, 2003
Emerging Company Profile

Corporate Profile

GenOdyssee S.A. Les Ulis, France Technology: Functional SNP discovery and validation applied to genes coding for therapeutic proteins Disease focus: Viral infection, cancer, anemia, autoimmune disease Clinical status: Preclinical Founded: 1999 by Jean-Louis Escary Corporate...
BioCentury | Sep 30, 2002
Company News

GenOdyssee board of directors update

GenOdyssee S.A. , Les Ulis, France Business: Functional genomics Appointed: Jean-Marc Giry, VP of strategic planning; Philippe Remes, VP of investor relations; Jean Maral VP of preclinical and clinical affairs WIR Staff...
BioCentury | Sep 30, 2002
Company News

GenOdyssee management update

GenOdyssee S.A. , Les Ulis, France Business: Functional genomics Hired: Jean-Marc Giry as VP of strategic planning, formerly X-PM Transition Partners; Philippe Remes as VP of investor relations, formerly VP of Northern Europe at Tyco Healthcare...
BioCentury | Sep 23, 2002
Company News

GenOdyssee SA other research news

...and suggest that the IFN alpha variants are better tolerated than those on the market GenOdyssee...
BioCentury | Jan 14, 2002
Company News

GenOdyssee, Transgenomic sales and marketing update

...market nucleic acid analysis services performed by GenOdyssee in the U.S., EU, Switzerland and Japan. GenOdyssee S.A....
Items per page:
1 - 10 of 11